Corporate
India
Expanding care for the people who need it most
We’re not just developing specialty medicines.
We’re supporting the communities around them.
Some conditions are complex. Some are overlooked. Our Specialty business exists for both. We focus on treatments for conditions where new options can make a real difference.
Today, we’re expanding our portfolio across neurology — including Parkinson’s disease, migraine, and cluster headache — as well as endocrinology, such as hypothyroidism, and beyond. Our goal is simple: set a new standard of care where patients need it most.
What sets us apart
Innovation alone isn’t enough. We invest just as deeply in the experience around the medicine as we do in the science behind it.
Providers have the clinical tools, resources, and support they need to prescribe with confidence
Patients have real access to the medicines, guidance, and services that help them find the right therapy, stay on treatment, and thrive
Communities feel supported including our meaningful contributions to patient assistance foundations, advocacy organizations, and community programming
Joe Renda
Senior Vice President
Chief Commercial Officer- Specialty
Our integrated model — from R&D through advanced manufacturing — is built to bring specialty medicines to market faster, more reliably, and more affordably. Every therapy we launch reflects our commitment to improving outcomes and expanding access at the same time.
Therapies designed for addressing important medical needs — built on science, supported by access, and developed to raise the standard of care.
Explore our medicines across neurology, endocrinology, and other high-need therapeutic areas.
† Brekiya autoinjector is a prescription medicine used for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.
Brekiya autoinjector is not used to prevent migraine or used to treat other types of headaches such as hemiplegic migraines (that make you unable to move on one side of your body) or basilar migraines (rare form of migraine with aura). It is not known if Brekiya autoinjector is safe and effective in children.
Serious or potentially life-threatening reductions in blood flow to the brain or extremities due to interactions between dihydroergotamine (the active ingredient in Brekiya autoinjector) with strong CYP3A4 inhibitors (such as protease inhibitors and macrolide antibiotics) have been reported rarely. As a result, these medications should not be taken together.
* UNITHROID® (levothyroxine sodium) tablets is an oral prescription medicine for hypothyroidism. Do not use UNITHROID alone or in combination with other drugs for the treatment of obesity or weight loss.
We’re not just developing specialty medicines.
We’re supporting the communities around them.
